# Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Source: https://onco.cc/trials/nct05394103/  
OnCo record `nct05394103` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in metastatic cancer, run by Qurient Co., Ltd., now recruiting.

## Summary

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05394103 by Qurient Co., Ltd., with 130 participants planned, started 2022-08-30 and due to reach its primary completion in 2025-12-30. Interventions recorded: Q901, KEYTRUDA® (pembrolizumab). Conditions listed: Advanced Cancer, Metastatic Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05394103
- Phase: 1/2
- Setting: A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901Administered Via Intravenous Infusion as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Selected Advanced Solid Tumors With Cohort Expansions at the Recommended Phase 2 Dose
- Sponsor: Qurient Co., Ltd.
- Enrolled: 130

## Sources

- ClinicalTrials.gov NCT05394103: https://clinicaltrials.gov/study/NCT05394103

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct05394103.json